12:00 AM
May 13, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

LaViv azficel-T: Phase II started

Fibrocell began a double-blind, placebo-controlled Phase II trial to evaluate azficel-T in 21 patients with burn scars that restrict range of motion of jointed...

Read the full 97 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >